177Lu-PSMA-617放射性配体治疗与转移性去势抵抗性前列腺癌患者的结局
本研究纳入59例转移性去势抵抗性前列腺癌(mCRPC)患者,评估177Lu-PSMA-617放射性配体治疗的总生存期(OS)及预后预测因素。结果显示,首周期后PSA下降和初始碱性磷酸酶(ALP)<220 U/L与更长的OS相关,ALP<220 U/L还与更长的PSA无进展生存期(PPFS)相关。
要点
- 首周期177Lu-PSMA-617后PSA下降与更长OS相关(56 vs 29周,p=0.04)。
- 初始ALP<220 U/L与更长OS相关(56 vs 28周,p<0.01)。
- 仅ALP<220 U/L与更长PPFS显著相关(41 vs 18周,p<0.01)。
核心结论
- 首周期177Lu-PSMA-617后PSA下降及初始ALP<220 U/L是终末期mCRPC患者更长OS的预测因素。
- ALP<220 U/L还与更长的PPFS相关。
研究设计与样本
- 2014年12月至2017年1月连续纳入59例mCRPC患者(中位年龄72岁,IQR 66-76岁),均接受过至少一种新一代抗雄激素药物及化疗。
- 生化反应采用PCWG3标准评估,生存分析采用Kaplan-Meier估计和Cox比例风险模型,毒性采用CTCAE评估。
- 研究经当地伦理委员会批准。
主要发现
- 59例患者共接受159个周期177Lu-PSMA-617治疗(中位3周期,范围1-7),中位剂量6.11 GBq(IQR 5.9-6.3 GBq)。
- 中位随访24周(IQR 15-36周),76%(45例)患者有至少12周的随访数据(PCWG3)。
- PSA下降≥50%见于53%的患者,任何程度PSA下降见于91%的患者。
- 估计中位OS为32周,中位估计PPFS为18周。
- 初始ALP<220 U/L组OS为56周 vs ALP≥220 U/L组28周(p<0.01);首周期后PSA下降组OS为56周 vs 无下降组29周(p=0.04)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to evaluate the overall survival (OS) and to identify parameters predicting outcome in mCRPC patients treated with 177Lu-PSMA-617. METHODS: Between December 2014 and January 2017, 59 consecutive patients (median age 72 years; interquartile range, (IQR, 66-76 years) with mCRPC, who had been treated with at least one next-generation antihormonal drug as well as chemotherapy, were included in this study. Biochemical response was evaluated using Prostate Cancer Working Group 3 (PCWG3) criteria. Survival was evaluated using Kaplan-Meier estimates and Cox regression proportional hazards model. Toxicity was assessed using Common Toxicity Criteria for Adverse Events (CTCAE). The study was approved by the local ethics committee. RESULTS: The 59 patients were treated with a total of 159 cycles (median 3 cycles, range 1-7) of 177Lu-PSMA-617 (median dose 6.11 GBq, IQR 5.9-6.3 GBq). The median follow-up was 24 weeks (IQR 15-36 weeks). Follow-up data for at least 12 weeks (PCWG3) were available in 76% (45) of the patients. For outcome results data from all patients treated with at least one cycle were analysed. A decline in prostate-specific antigen (PSA) of ≥50% occurred in 53%, and a decline in PSA of any amount in 91% of patients. The estimated median OS was 32 weeks. An initial alkaline phosphatase (ALP) level <220 U/L and a PSA decline after the first cycle were associated with a longer OS (56 vs. 28 weeks, p < 0.01, and 56 vs. 29 weeks, p = 0.04, respectively). The median estimated PSA progression-free survival (PPFS) was 18 weeks. Only ALP level <220 U/L was significantly associated with a longer PPFS (41 vs. 18 weeks, p < 0.01). CONCLUSIONS: A PSA decline after the first cycle of 177Lu-PSMA-617 and an initial ALP level <220 U/L were predictors of a longer OS in patients with end-stage mCRPC. An ALP level <220 U/L was additionally associated with a longer PPFS.
引用
- Bräuer A, Grubert LS, Roll W, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28624848. doi:10.1007/s00259-017-3751-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。